Tarlatamab's role in SCLC
Published on 15 October 2026
Dr Luis Raez reviews recent developments in tarlatamab for small cell lung cancer, highlighting findings from the DeLLphi-304 study, which demonstrated an overall survival benefit compared with standard chemotherapy in previously treated patients.
He discusses the potential role of tarlatamab in patients with brain metastases and emerging data on combining tarlatamab with immune checkpoint inhibitors as maintenance treatment.
He also explores findings from the DeLLphi-309 study investigating extended dosing intervals, which could reduce the frequency of clinic visits while maintaining treatment activity and improving convenience and quality of life for patients.
Finally, he considers the broader potential of emerging therapeutic targets to improve outcomes in small cell lung cancer.